Patent number: 5863916
Abstract: Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable salts thereof; wherein n is zero or 1; R.sup.4, R.sup.5, R.sup.6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R.sup.c and R.sup.d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor. Also disclosed are methods of treating pathophysiologic conditions associated with neuronal degeneration, convulsions, anxiety, chronic pain, pyschosis, opiate tolerance, and inducing anesthesia.
Type:
Grant
Filed:
February 4, 1997
Date of Patent:
January 26, 1999
Assignees:
State of Oregon, Acting by and Through the Oregon State Board of Higher-Education, Acting for and on Behalf of the Oregon Health Sciences University and The University of Oregon, The Regents of the University of California, Cocensys, Inc.
Inventors:
Sui Xiong Cai, John F. W. Keana, Eckard Weber